Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting.

Brixner DI, McAdam-Marx C, Ye X, Boye KS, Nielsen LL, Wintle M, Misurski D, Fabunmi R

Diabetes, obesity & metabolism1 Dec 2009Cited by 27 (Europe PMC)

PMID19930004DOI10.1111/j.1463-1326.2009.01081.xPepBankPUB-19930004

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanObservational studyEfficacy outcome
In patients with type 2 diabetes, exenatide initiation was linked to a mean A1C change of -0.8% from baseline at 6 months.
In plain wordsIn type 2 diabetes, exenatide initiation was linked to lower A1C than baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseA1C
Study
n = 1,709
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
A1C change
−0.8%
6 months after exenatide initiation, change from baseline (s.e.m. 0.05)
Source sentences
Summary
The overall mean A1C reduction (s.e.m.) at 6 months was -0.8% (0.05) (p<0.001), weight loss was -3.2 kg (0.14) (p<0.001), blood pressure (BP) lowering was -1.9 mmHg (0.46) systolic blood pressure (SBP) (p<0.001) and -0.5 mmHg (0.27) diastolic blood pressure (DBP) (p = 0.078).
3 context sentences(design, population, supporting numbers)
Summary · context
This study evaluated changes in clinical effectiveness measures of patients with type 2 diabetes initiating exenatide therapy in a real-world setting.
Summary · context
Baseline clinical measures were documented from 45 days prior up to 15 days after exenatide initiation and follow-up measures documented at 6 months +/- 45 days.
Summary · context
A total of 1709 patients were identified for study inclusion.
Report a problemFND-1993000401
02HumanObservational studyEfficacy outcome
In patients with type 2 diabetes, exenatide initiation was linked to a mean weight change of -3.2 kg from baseline.
In plain wordsIn type 2 diabetes, exenatide initiation was linked to lower body weight than baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight
Study
n = 1,709
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Weight change
−3.2 kg
6 months after exenatide initiation, change from baseline (s.e.m. 0.14)
Source sentences
Summary
The overall mean A1C reduction (s.e.m.) at 6 months was -0.8% (0.05) (p<0.001), weight loss was -3.2 kg (0.14) (p<0.001), blood pressure (BP) lowering was -1.9 mmHg (0.46) systolic blood pressure (SBP) (p<0.001) and -0.5 mmHg (0.27) diastolic blood pressure (DBP) (p = 0.078).
3 context sentences(design, population, supporting numbers)
Summary · context
This study evaluated changes in clinical effectiveness measures of patients with type 2 diabetes initiating exenatide therapy in a real-world setting.
Summary · context
Baseline clinical measures were documented from 45 days prior up to 15 days after exenatide initiation and follow-up measures documented at 6 months +/- 45 days.
Summary · context
A total of 1709 patients were identified for study inclusion.
Report a problemFND-1993000402
03HumanObservational studyEfficacy outcome
In type 2 diabetes, exenatide initiation was linked to significantly lower systolic blood pressure than baseline.
In plain wordsIn type 2 diabetes, exenatide initiation was linked to lower systolic blood pressure than baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseSystolic blood pressure
Study
n = 1,709
Comparator
Baseline
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Systolic blood pressure change
−1.9 mmHg
6 months after exenatide initiation, change from baseline (s.e.m. 0.46)
Source sentences
Summary
The overall mean A1C reduction (s.e.m.) at 6 months was -0.8% (0.05) (p<0.001), weight loss was -3.2 kg (0.14) (p<0.001), blood pressure (BP) lowering was -1.9 mmHg (0.46) systolic blood pressure (SBP) (p<0.001) and -0.5 mmHg (0.27) diastolic blood pressure (DBP) (p = 0.078).
3 context sentences(design, population, supporting numbers)
Summary · context
This study evaluated changes in clinical effectiveness measures of patients with type 2 diabetes initiating exenatide therapy in a real-world setting.
Summary · context
Baseline clinical measures were documented from 45 days prior up to 15 days after exenatide initiation and follow-up measures documented at 6 months +/- 45 days.
Summary · context
A total of 1709 patients were identified for study inclusion.
Report a problemFND-1993000403
04HumanObservational studyEfficacy outcome
In type 2 diabetes, diastolic blood pressure did not significantly change from baseline after exenatide initiation.
In plain wordsIn type 2 diabetes, exenatide initiation was not linked to a significant diastolic blood pressure change from baseline.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeDiastolic blood pressure
Study
n = 1,709
Comparator
Baseline
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Diastolic blood pressure change
−0.5 mmHg
6 months after exenatide initiation, change from baseline (s.e.m. 0.27; p = 0.078)
Source sentences
Summary
The overall mean A1C reduction (s.e.m.) at 6 months was -0.8% (0.05) (p<0.001), weight loss was -3.2 kg (0.14) (p<0.001), blood pressure (BP) lowering was -1.9 mmHg (0.46) systolic blood pressure (SBP) (p<0.001) and -0.5 mmHg (0.27) diastolic blood pressure (DBP) (p = 0.078).
3 context sentences(design, population, supporting numbers)
Summary · context
This study evaluated changes in clinical effectiveness measures of patients with type 2 diabetes initiating exenatide therapy in a real-world setting.
Summary · context
Baseline clinical measures were documented from 45 days prior up to 15 days after exenatide initiation and follow-up measures documented at 6 months +/- 45 days.
Summary · context
A total of 1709 patients were identified for study inclusion.
Report a problemFND-1993000404
05HumanObservational studyEfficacy outcome
In type 2 diabetes, exenatide initiation was linked to lower LDL cholesterol than baseline.
In plain wordsIn type 2 diabetes, exenatide initiation was linked to lower LDL cholesterol than baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseLDL cholesterol
Study
n = 1,709
Comparator
Baseline
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
LDL change
−7.4 mg/dl
6 months after exenatide initiation, change from baseline (s.e.m. 1.7)
Source sentences
Summary
Changes in low-density lipoprotein (LDL), triglycerides and HDL were -7.4 mg/dl (1.7) (p<0.001), -23.2 mg/dl (6.7) (p = 0.001) and -0.8 mg/dl (0.33) (p = 0.012) respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
This study evaluated changes in clinical effectiveness measures of patients with type 2 diabetes initiating exenatide therapy in a real-world setting.
Summary · context
Baseline clinical measures were documented from 45 days prior up to 15 days after exenatide initiation and follow-up measures documented at 6 months +/- 45 days.
Summary · context
A total of 1709 patients were identified for study inclusion.
Report a problemFND-1993000405
06HumanObservational studyEfficacy outcome
In type 2 diabetes, exenatide initiation was linked to lower triglycerides than baseline.
In plain wordsIn type 2 diabetes, exenatide initiation was linked to lower triglycerides than baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTriglycerides
Study
n = 1,709
Comparator
Baseline
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Triglyceride change
−23.2 mg/dl
6 months after exenatide initiation, change from baseline (s.e.m. 6.7)
Source sentences
Summary
Changes in low-density lipoprotein (LDL), triglycerides and HDL were -7.4 mg/dl (1.7) (p<0.001), -23.2 mg/dl (6.7) (p = 0.001) and -0.8 mg/dl (0.33) (p = 0.012) respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
This study evaluated changes in clinical effectiveness measures of patients with type 2 diabetes initiating exenatide therapy in a real-world setting.
Summary · context
Baseline clinical measures were documented from 45 days prior up to 15 days after exenatide initiation and follow-up measures documented at 6 months +/- 45 days.
Summary · context
A total of 1709 patients were identified for study inclusion.
Report a problemFND-1993000406
07HumanObservational studyEfficacy outcome
In type 2 diabetes, exenatide initiation was linked to lower HDL cholesterol than baseline.
In plain wordsIn type 2 diabetes, exenatide initiation was linked to lower HDL cholesterol than baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHDL cholesterol
Study
n = 1,709
Comparator
Baseline
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
HDL change
−0.8 mg/dl
6 months after exenatide initiation, change from baseline (s.e.m. 0.33)
Source sentences
Summary
Changes in low-density lipoprotein (LDL), triglycerides and HDL were -7.4 mg/dl (1.7) (p<0.001), -23.2 mg/dl (6.7) (p = 0.001) and -0.8 mg/dl (0.33) (p = 0.012) respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
This study evaluated changes in clinical effectiveness measures of patients with type 2 diabetes initiating exenatide therapy in a real-world setting.
Summary · context
Baseline clinical measures were documented from 45 days prior up to 15 days after exenatide initiation and follow-up measures documented at 6 months +/- 45 days.
Summary · context
A total of 1709 patients were identified for study inclusion.
Report a problemFND-1993000407
08HumanObservational studyEfficacy outcome
After exenatide initiation, A1C reduction ranged from -1.1% in the highest to -0.65% in the lowest weight loss quartile.
In plain wordsIn type 2 diabetes, greater weight loss after exenatide initiation was linked to greater A1C reduction across quartiles.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseA1C reduction by weight loss quartile
Study
n: not reported in source
Comparator
Lowest weight loss quartile
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
A1C reduction across weight loss quartiles
−1.1 to −0.65%
highest to lowest weight loss quartile at 6 months
Source sentences
Summary
In a quartile analysis by weight loss, mean A1C reduction ranged from -1.1 to -0.65% in the highest to lowest weight loss quartiles respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
This study evaluated changes in clinical effectiveness measures of patients with type 2 diabetes initiating exenatide therapy in a real-world setting.
Summary · context
Baseline clinical measures were documented from 45 days prior up to 15 days after exenatide initiation and follow-up measures documented at 6 months +/- 45 days.
Summary · context
A total of 1709 patients were identified for study inclusion.
Report a problemFND-1993000408

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.